Status:
COMPLETED
Correlation of Oxidative Stress and Oocyte Quality in Fertility Preservation
Lead Sponsor:
Clinique Ovo
Collaborating Sponsors:
Ferring Pharmaceuticals
Conditions:
Fertility Preservation
Eligibility:
FEMALE
18-37 years
Phase:
NA
Brief Summary
Whether it is for oncology or personal reasons, fertility preservation allows participants to preserve their oocytes (eggs) at their current age and condition for a better chance of having a baby in t...
Eligibility Criteria
Inclusion
- \- Women 18 to 37 years of age inclusively eligible for fertility preservation for either social or oncology reason
Exclusion
- Pregnancy and lactation
- Uncontrolled thyroid or adrenal dysfunction
- Tumours of the hypothalamus or pituitary gland
- Ovarian enlargement not due to polycystic ovarian syndrome
- Gynaecological haemorrhages of unknown aetiology
- Endometriosis stage III/IV
- Use of hormonal preparations (except for thyroid medication) during the last menstrual cycle
- Use of Coenzyme Q10 during the stimulation cycle
- Renal and/or hepatic impairment
- Hypersensitivity to any active ingredient or excipients in follitropin delta and/or HP-hMG
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 3 2025
Estimated Enrollment :
179 Patients enrolled
Trial Details
Trial ID
NCT05372549
Start Date
June 1 2022
End Date
January 3 2025
Last Update
March 20 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Olive Fertility Centre
Vancouver, British Columbia, Canada, V5Z 3X7
2
Ottawa Fertility Centre
Ottawa, Ontario, Canada, K2C 3V4
3
Clinique Ovo
Montreal, Quebec, Canada, H4P 2S4